

The role of S-methylisothiourea hemisulfate as inducible nitric oxide synthase inhibitor against kidney iron deposition in iron overload rats

Maryam Maleki¹, Melika Samadi¹, Mehrangiz Khanmoradi², Mehdi Nematbakhsh^{1,2,3}, Ardeshir Talebi¹, Hamid Nasri¹

¹Water and Electrolytes Research Center, Isfahan University of Medical Sciences, ²Department of Physiology, Isfahan University of Medical Sciences, ³Isfahan MN Institute of Basic and Applied Sciences Research, Isfahan, Iran

Abstract

Background: Iron dextran is in common use to maintain iron stores. However, it is potentially toxic and may lead to iron deposition (ID) and impair functions of organs. Iron overload can regulate the expression of inducible nitric oxide synthase (iNOS) in some cells that has an important role in tissue destruction. S-methylisothiourea hemisulfate (SMT) is a direct inhibitor of iNOS, and this study was designed to investigate the effect of SMT against kidney ID in iron overload rats.

Materials and Methods: 24 Wistar rats (male and female) were randomly assigned to two groups. Iron overloading was performed by iron dextran 100 mg/kg/day every other day for 2 weeks. In addition, during the study, groups 1 and 2 received vehicle and SMT (10 mg/kg, ip), respectively. Finally, blood samples were obtained, and the kidneys were prepared for histopathological procedures.

Results: SMT significantly reduced the serum levels of creatinine and blood urea nitrogen. However, SMT did not alter the serum levels of iron and nitrite, and the kidney tissue level of nitrite. Co-administration of SMT with iron dextran did not attenuate the ID in the kidney.

Conclusion: SMT, as a specific iNOS inhibitor, could not protect the kidney from ID while it attenuated the serum levels of kidney function biomarkers.

Key Words: Iron deposition, kidney, nitric oxide synthase, S-methylisothiourea hemisulfate

Address for correspondence:

Prof. Mehdi Nematbakhsh, Water and Electrolytes Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

E-mail: nematbakhsh@med.mui.ac.ir

Received: 05.12.2014, Accepted: 21.01.2015

INTRODUCTION

Iron is essential for various processes in the human body such as oxygen transport, energy metabolism, and DNA synthesis.^[1] Although iron is a vital mineral nutrient for living cells, it is potentially toxic.^[2] The critical role of iron in transferring oxygen, metabolic reactions, cellular respiration, production of oxygen radicals, DNA synthesis, and repair is balanced toward iron harmful effects, which lead to iron deposition (ID), oxidative stress, and finally cellular damage.^[3,4] It is

Access this article online	
Quick Response Code:	Website: www.advbiores.net
	DOI: 10.4103/2277-9175.183145

Copyright: © 2016 Maleki. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

How to cite this article: Maleki M, Samadi M, Khanmoradi M, Nematbakhsh M, Talebi A, Nasri H. The role of S-methylisothiourea hemisulfate as inducible nitric oxide synthase inhibitor against kidney iron deposition in iron overload rats. *Adv Biomed Res* 2016;5:96.

essential to control iron homeostasis tightly to balance its role as a necessary element for survival versus its toxic effects.^[3] Regular blood transfusion in thalassemia patients causes iron overload and hemosiderosis in many organs such as the liver, kidney, and heart,^[5] because the body has no physiological mechanism to actively excrete excess iron.^[6]

Almost all patients treated by erythropoiesis-stimulating agents should receive additional iron supplements.^[7] Parenteral iron transfusion should be administered with exact attention to the total body iron storage or presence of active inflammation; otherwise, it results in iron overload, oxidative stress, and inflammation.^[7,8] Regulation of iron metabolism is so important since both iron deficiency and iron overload can cause disease even in the brain, which is highly influenced by iron metabolism defects and consequently accumulation and ID.^[9] Iron overload is one of the common iron-related toxicities. Excess iron has a central role in producing reactive oxygen species (ROS) and reactive nitrogen species (RNS), which can damage biological molecules such as lipids, proteins, and nucleic acids; resulting in oxidative stress and various diseases.^[4] Furthermore, it is reported that iron overload can increase inducible nitric oxide (NO) synthase (iNOS) in some organs.^[10,11] S-methylisothiourrea hemisulfate (SMT); a nonamino acid analogue of L-arginine is one of the inhibitory agents that reduces iNOS effects. The agent is shown to be 10–30 times more effective and powerful than other iNOS inhibitors *in vitro*.^[12] SMT inhibits NO production, which in turn reduces endogenous NO concentration.^[13] Due to increase of iNOS in some organs^[10,11] by iron overloading, it is hypothesized that inhibition of iNOS may attenuate iron overloading or at least its side effects. Therefore, in the current study, we attempted to perform a moderate iron overload model in 2 weeks, and the role of SMT against iron overload was investigated.

MATERIALS AND METHODS

Animals

Twenty-four adult Wistar rats (12 males and 12 females; 169.83 ± 3.54 g) were used. The animals were fed on conventional diets and had free access to tap water. The rats were kept at the room temperature (23–25°C) and maintained under standard conditions of light (light/dark: 12:12 h). The experiments were carried out in accordance with the guidelines of the Ethics Committee of Isfahan University of Medical Sciences.

Experimental protocol

The animals were randomly divided into two experimental groups. Group 1 (six male and six female) received iron dextran (Vifor Inc., Switzerland)

100 mg/kg, ip every other day and saline as a vehicle for SMT every day for 2 weeks.

Group 2 (six male and six female) received iron dextran regimen the same as Group 1 and SMT (10 mg/kg, ip) every day for 2 weeks.

We used equal sample size of male and female rats in each group of experiments to include the possible gender effect on the results.

At the end of the experiment, the blood samples were obtained by heart puncture under chloral hydrate anesthetization. Then, the rats were sacrificed, and kidneys, uterus (in females), and testis (in males) were removed and weighted immediately. The kidneys were also prepared for histopathological procedures. The weight of animals was recorded on a daily basis.

Measurements

The levels of serum creatinine (Cr) and blood urea nitrogen (BUN) were determined using quantitative diagnostic kits (Pars Azmoon, Iran). The serum level of nitrite (stable NO metabolite) was measured using a colorimetric kit (Promega Corporation, USA). The serum level of iron was measured using a diagnostic kit with the photometric method.

Histopathological procedures

The removed kidneys were fixed in 10% neutral formalin solution to examine ID in the kidney. The kidney ID was evaluated by a pathologist who was blind to the study. The level of ID in the kidney tissue was scored on the basis of the intensity of tissue in the range of 0–100%, and 0 was assigned to normal kidney tissue without any ID.

Statistical analysis

Data are expressed as mean \pm standard error of the mean. The serum levels of BUN, Cr, iron, and nitrite; kidney nitrite, and the percentage of ID in kidney tissue were compared between the groups using the Student's *t*-test. $P \leq 0.05$ was considered statistically significant.

RESULTS

Bodyweight change

No significant changes in body ($P = 0.45$), kidney ($P = 0.62$), testis (in male, $P = 0.18$), and uterus (in female, $P = 0.19$) weights were observed between the groups [Figure 1 and Table 1].

Effect of S-methylisothiourrea hemisulfate on serum blood urea nitrogen, creatinine, iron, and nitrite levels
S-methylisothiourrea hemisulfate significantly reduced the serum levels of Cr ($P = 0.053$) and BUN ($P = 0.00$)

as kidney functional parameters [Figure 1]. However, SMT did not alter the serum levels of iron and nitrite. The kidney tissue level of nitrite also did not change by SMT [Figure 1, Table 1].

Iron deposition in kidney tissue

Histological investigations demonstrated ID in the kidney tissue of both groups. However, no statistical difference ($P = 0.72$) was detected between the groups [Figure 1]. This finding revealed that SMT as a selective iNOS inhibitor could not attenuate the ID in the kidney. The sample images of ID in kidney tissue are provided in Figure 2.

DISCUSSION

Chronic iron overload result from several conditions, including genetic defects of iron uptake and storage, frequent red blood cell transfusions, metabolic alterations, chronic liver disease, or excessive iron intake.^[14] Considering the importance of chronic iron overload, in this study, the role of simultaneous use

of SMT with iron against ID was investigated. SMT is an iNOS inhibitor, and some studies have shown the specificity of SMT for iNOS.^[12,15] Nitrite is also considered as an indicator of NO production.^[16] We found that simultaneous use of SMT and iron did not attenuate the intensity of ID in the kidney.

Nitric oxide plays an important role in many physiological and pathophysiological processes.^[17,18] It is an inorganic radical produced by NO synthase (NOS).^[18,19] Three isoforms of NOS; namely, neuronal NOS (nNOS, type 1), inducible NOS (iNOS, type 2), and endothelial NOS (eNOS, type 3), have been identified that produce NO from L-arginine.^[18,19] The iNOS isoform produces large quantities of NO that can result in tissue damage or death.^[20] Although plasma nitrite and nitrate are not significant biomarkers of oxidative stress, they reflect the presence of NO species in plasma.^[21] In addition, nitrite more corresponds to NO produced by eNOS in vasculature under physiological conditions rather than iNOS or nNOS.^[22] Accordingly, it could be assumed as the reason for insignificant difference in nitrite levels




Figure 1: The serum level of blood urea nitrogen, creatinine, bodyweight change (Δ BW), and percentage of iron deposition (ID) in kidney tissue (ID) in two iron overload groups treated with vehicle and S-methylisothiourea hemisulfate. The P value obtained by the Student's t -test

Table 1: The serum levels of Fe and SN, KN, and KW/100 g BW, TW/100 g BW, and UW/100 g BW/100 g BW in two iron overload groups treated with vehicle and SMT

Group	Fe (mg/dl)	SN (μ mol/L)	KN (μ mol/L)	KW/100 g BW	TW/100 g BW	UW/100 g BW
Iron+vehicle	270.9 \pm 18.2	13.3 \pm 1.9	35.0 \pm 3.9	0.722 \pm 0.026	0.95 \pm 0.15	0.064 \pm 0.013
Iron+SMT	268.7 \pm 16.3	14.2 \pm 1.9	41.9 \pm 5.4	0.736 \pm 0.010	1.34 \pm 0.22	0.041 \pm 0.002
P	0.92	0.75	0.30	0.62	0.18	0.19

The P value obtained by the Student's t -test. SMT: S-methylisothiourea hemisulfate, Fe: Iron, SN: Nitrite, KN: Kidney level of nitrite, KW: Kidney weight, BW: Body weight, TW: Testis weight, UW: Uterus weight




Figure 2: Sample images of iron deposition in two groups of experiment

between the two groups.^[23,24] It was reported that chronic iron overload result in ID in the glomeruli and proximal tubules with various kidney injuries and evidence of augmentative ROS activity, increased ROS-mediated inactivation, sequestration of NO, and compensatory up-regulation of renal eNOS and iNOS expressions.^[25] We used SMT that significantly inhibit iNOS activity without significant effects on constitutive NOS.^[26,27] In the current study, the groups were insignificantly different in the serum level of nitrite, which is a marker of NO production from endothelium^[28] and endothelium function.^[29] The underlying reason for the difference could be up-regulation of renal eNOS expressions in chronic iron overload. We did not measure the serum nitrate level, another metabolite of NO because plasma nitrate level is influenced by some other NOS independent factors too, and it cannot be a good indicator of NOS activity.^[29,30]

Testis and uterus weight respectively in male and female rats (per 100 g BW) in two iron overload groups treated with vehicle and SMT were insignificantly different. In another study with the same chronic iron overload condition, it was reported that no changes in bodyweights and testis weight were observed in iron overload group,^[14] and this model of chronic iron overload produced a mild oxidative damage in rat testis.^[14] It has been reported that iron overload cause a significant decrease in testis content of lipid soluble antioxidants, inversely correlated with tissue iron concentration, but the acute iron overload did not affect testis weight.^[31] In addition, some *in vitro* studies have shown that NO is one of the inflammatory vasodilatory factors that can suppress steroidogenesis in Leydig cells even in the absence of inflammation. This is produced by one of the three NOS enzymes, especially iNOS, which is calcium independent and is expressed in normal testis. NOS inhibitors primarily reduce NO and increase testosterone levels. However, after few hours, testosterone level and spermatogenesis decline due to the low concentration of NO and consequently reduced blood flow, which affect Leydig and Sertoli

cells. This complex role of iNOS and NO in testis is similar to the condition of inflammation and ROS production, which should be in an appropriate balance with NO. Therefore, iNOS inhibitors influence normal and inflamed testis similarly.^[32,33]

It was reported that iron overload causes an increase in BUN and Cr.^[15,34,35] Urea specifically and reversibly inhibits the inducible NO synthesis in macrophages.^[36] Thus, possibly in our study simultaneous with loss of BUN, iNOS activity enhanced NO synthesis and therefore compensated the SMT function. SMT, a nonamino acid analogue of L-arginine, is a direct inhibitor of iNOS that inhibits the function of iNOS competitively (in a dose-dependent manner), so does not interfere with the production of iNOS.^[15,37]

CONCLUSION

S-methylisothiourea hemisulfate as a specific iNOS inhibitor could not prevent ID in kidney while it attenuates the serum levels of kidney function biomarkers; BUN and Cr. However, the increase in iNOS by iron overload^[10,11] may be prevented by other specific iNOS inhibitors.

ACKNOWLEDGMENTS

This study was supported by the Isfahan University of Medical Sciences.

REFERENCES

- Hou Y, Zhang S, Wang L, Li J, Qu G, He J, *et al.* Estrogen regulates iron homeostasis through governing hepatic hepcidin expression via an estrogen response element. *Gene* 2012;511:398-403.
- Zhang Y, Zhang Y, Xie Y, Gao Y, Ma J, Yuan J, *et al.* Multitargeted inhibition of hepatic fibrosis in chronic iron-overloaded mice by *Salvia miltiorrhiza*. *J Ethnopharmacol* 2013;148:671-81.
- Adams RL, Bird RJ. Safety and efficacy of deferasirox in the management of transfusion-dependent patients with myelodysplastic syndrome and aplastic anaemia: a perspective review. *Ther Adv Hematol* 2013;4:93-102.
- Lu N, Li X, Li J, Xu W, Li H, Gao Z. Nitritative and oxidative modifications of enolase are associated with iron in iron-overload rats and *in vitro*. *J Biol Inorg Chem* 2011;16:481-90.
- Koliakos G, Papachristou F, Koussi A, Perifanis V, Tsatra I, Souliou E, *et al.* Urine biochemical markers of early renal dysfunction are associated with iron overload in beta-thalassaemia. *Clin Lab Haematol* 2003;25:105-9.
- Kohgo Y, Ikuta K, Ohtake T, Torimoto Y, Kato J. Body iron metabolism and pathophysiology of iron overload. *Int J Hematol* 2008;88:7-15.
- Vaziri ND. Understanding iron: Promoting its safe use in patients with chronic kidney failure treated by hemodialysis. *Am J Kidney Dis* 2013;61:992-1000.
- Rusovici A, Ibrahim S, Sood S, Maher J, Gerula C, Kaluski E, *et al.* Extensive myocardial iron deposition in a patient with hepatitis C. *Tex Heart Inst J* 2012;39:281-3.
- Schneider SA, Bhatia KP. Excess iron harms the brain: The syndromes of neurodegeneration with brain iron accumulation (NBIA). *J Neural Transm* 2013;120:695-703.
- Nematbakhsh M, Pezeshki Z, Moaedi BA, Eshraghi-Jazi F, Talebi A, Nasri H, *et al.* Protective role of silymarin and deferoxamine against

- iron dextran-induced renal iron deposition in male rats. *Int J Prev Med* 2013;4:286-92.
11. Cornejo P, Varela P, Videla LA, Fernández V. Chronic iron overload enhances inducible nitric oxide synthase expression in rat liver. *Nitric Oxide* 2005;13:54-61.
 12. Almeida RM, Sousa JB, Ribeiro PR, Silva SM, Firmino MA, Oliveira PG. Evaluation of the effects of S-methylisothiourea hemisulfate, an inducible nitric oxide synthase inhibitor, on the healing of colonic anastomosis in rats. *Acta Cir Bras* 2012;27:892-6.
 13. Pechenik JA, Cochrane DE, Li W, West ET, Pires A, Leppo M. Nitric oxide inhibits metamorphosis in larvae of *Crepidula fornicata*, the slippershell snail. *Biol Bull* 2007;213:160-71.
 14. Lucesoli F, Fraga CG. Oxidative stress in testes of rats subjected to chronic iron intoxication and alpha-tocopherol supplementation. *Toxicology* 1999;132:179-86.
 15. Szabó C, Southan GJ, Thiernemann C. Beneficial effects and improved survival in rodent models of septic shock with S-methylisothiourea sulfate, a potent and selective inhibitor of inducible nitric oxide synthase. *Proc Natl Acad Sci U S A* 1994;91:12472-6.
 16. Wen S, Huang TH, Li GQ, Yamahara J, Roufogalis BD, Li Y. Bromelain improves decrease in defecation in postoperative rats: Modulation of colonic gene expression of inducible nitric oxide synthase. *Life Sci* 2006;78:995-1002.
 17. Takimoto Y, Aoyama T, Keyamura R, Shinoda E, Hattori R, Yui Y, *et al.* Differential expression of three types of nitric oxide synthase in both infarcted and non-infarcted left ventricles after myocardial infarction in the rat. *Int J Cardiol* 2000;76:135-45.
 18. Chen LW, Hsu CM, Wang JS, Chen JS, Chen SC. Specific inhibition of iNOS decreases the intestinal mucosal peroxynitrite level and improves the barrier function after thermal injury. *Burns* 1998;24:699-705.
 19. Ohsugi S, Iwasaki Y, Takemura Y, Nagata K, Harada H, Yokomura I, *et al.* An inhaled inducible nitric oxide synthase inhibitor reduces damage of Candida-induced acute lung injury. *Biomed Res* 2007;28:91-9.
 20. Nakanishi H, Zhang J, Koike M, Nishioku T, Okamoto Y, Kominami E, *et al.* Involvement of nitric oxide released from microglia-macrophages in pathological changes of cathepsin D-deficient mice. *J Neurosci* 2001;21:7526-33.
 21. Pimková K, Chrástínová L, Suttar J, Štikarová J, Kotlín R, Cermák J, *et al.* Plasma levels of amino thiols, nitrite, nitrate, and malondialdehyde in myelodysplastic syndromes in the context of clinical outcomes and as a consequence of iron overload. *Oxid Med Cell Longev* 2014;2014:416028.
 22. Tsai SK, Hung LM, Fu YT, Cheng H, Nien MW, Liu HY, *et al.* Resveratrol neuroprotective effects during focal cerebral ischemia injury via nitric oxide mechanism in rats. *J Vasc Surg* 2007;46:346-53.
 23. Shiva S. Nitrite: A physiological store of nitric oxide and modulator of mitochondrial function. *Redox Biol* 2013;1:40-44.
 24. Li H, Forstermann U. Pharmacological prevention of eNOS uncoupling. *Curr Pharm Des* 2014;20:3595-606.
 25. Zhou XJ, Laszik Z, Wang XQ, Silva FG, Vaziri ND. Association of renal injury with increased oxygen free radical activity and altered nitric oxide metabolism in chronic experimental hemosiderosis. *Lab Invest* 2000;80:1905-14.
 26. Wildhirt SM, Suzuki H, Horstman D, Weismüller S, Dudek RR, Akiyama K, *et al.* Selective modulation of inducible nitric oxide synthase isozyme in myocardial infarction. *Circulation* 1997;96:1616-23.
 27. Zhao T, Xi L, Chelliah J, Levasseur JE, Kukreja RC. Inducible nitric oxide synthase mediates delayed myocardial protection induced by activation of adenosine A(1) receptors: evidence from gene-knockout mice. *Circulation* 2000;102:902-7.
 28. Kelm M, Preik-Steinhoff H, Preik M, Strauer BE. Serum nitrite sensitively reflects endothelial NO formation in human forearm vasculature: Evidence for biochemical assessment of the endothelial L-arginine-NO pathway. *Cardiovasc Res* 1999;41:765-72.
 29. Hetzel J, Balletshofer B, Rittig K, Walcher D, Kratzer W, Hombach V, *et al.* Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. *Arterioscler Thromb Vasc Biol* 2005;25:1804-9.
 30. Metzger IF, Sertorio JT, Tanus-Santos JE. Relationship between systemic nitric oxide metabolites and cyclic GMP in healthy male volunteers. *Acta Physiol (Oxf)* 2006;188:123-7.
 31. Lucesoli F, Fraga CG. Oxidative damage to lipids and DNA concurrent with decrease of antioxidants in rat testes after acute iron intoxication. *Arch Biochem Biophys* 1995;316:567-71.
 32. O'Bryan MK, Schlatt S, Gerdspraser O, Phillips DJ, de Kretser DM, Hedger MP. Inducible nitric oxide synthase in the rat testis: Evidence for potential roles in both normal function and inflammation-mediated infertility. *Biol Reprod* 2000;63:1285-93.
 33. Kolasa A, Marchlewicz M, Kurzawa R, Glabowski W, Trybek G, Wenda-Rózewicka L, *et al.* The expression of inducible nitric oxide synthase (iNOS) in the testis and epididymis of rats with a dihydrotestosterone (DHT) deficiency. *Cell Mol Biol Lett* 2009;14:511-27.
 34. Kudo H, Suzuki S, Watanabe A, Kikuchi H, Sassa S, Sakamoto S. Effects of colloidal iron overload on renal and hepatic siderosis and the femur in male rats. *Toxicology* 2008;246:143-7.
 35. Gupta A, Sharma S, Chopra K. Reversal of iron-induced nephrotoxicity in rats by molsidomine, a nitric oxide donor. *Food Chem Toxicol* 2008;46:537-43.
 36. Prabhakar SS, Zeballos GA, Montoya-Zavala M, Leonard C. Urea inhibits inducible nitric oxide synthase in macrophage cell line. *Am J Physiol* 1997;273:C1882-8.
 37. Mitchell LM, Kennedy CR, Hartshorne GM. Pharmacological manipulation of nitric oxide levels in mouse follicle cultures demonstrates key role of extrafollicular control of ovulation. *Hum Reprod* 2004;19:1705-12.

Source of Support: Nil, **Conflict of Interest:** None declared.